• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

Drug Delivery Business

  • Clinical Trials
  • Research & Development
  • Drug-Device Combinations
  • FDA
  • Pharmaceuticals
  • Policy

European task force: Docs should favor drug-eluting stents over bioresorbable scaffolds

October 12, 2017 By Sarah Faulkner

Abbott's Absorb bioresorbable stentPhysicians should not use bioresorbable scaffolds in place of current-generation drug-eluting stents, according to a report from the European Society of Cardiology and European Association of Percutaneous Cardiovascular Inventions.

The ECS/EAPCI report says that as long as concerns remain about the increased risk of myocardial infarction and scaffold thrombosis linked with bioresorbable scaffolds, physicians should favor using drug-eluting stents.

The report, published in EuroIntervention, focused on five bioresorbable scaffolds that held CE Mark approval in Europe while the report was compiled. In the meantime, however, Abbott (NYSE:ABT) pulled its Absorb device from the market, leaving behind Elixir Medical‘s DESolve, Reva Medical‘s (ASX:RVA) Fantom, Biotronik‘s Magmaris and Arterial Remodeling Technologies bioresorbable scaffold.

Abbott’s product boasts the most clinical trial data out of all its competitors and longer-term outcomes have shown an risk of target-vessel MI and scaffold thrombosis compared to Abbott’s Xience everolimus-eluting stent.

In July, Boston Scientific announced it would terminate its Renuvia bioresorbable coronary stent program, saying that the company wanted to focus its development efforts elsewhere.

The report also gives recommendations for how physicians should use dual antiplatelet therapy in patients who have been treated with a bioresorbable scaffold, according to TCTMD.

The task force said that treating a patient with aspirin and a P2Y12 inhibitor is mandatory after the patient has been implanted with a bioresorbable scaffold to reduce the risk of thrombosis. But the report cautions that the optimal duration of such a treatment is not yet known.

The report recommended that patients currently taking DAPT after scaffold implantation should continue for at least three years with Absorb.

If any of the approved bioresorbable scaffolds are used, the task force recommended lesion assessment with intravascular imaging and other steps.

The report also says that clinical studies can use a non-inferiority study design with a one year endpoint, but longer-term follow-up should include a superiority assessment.

See the best minds in medtech live at DeviceTalks West, Dec. 11–12 in Orange County, Calif.

Filed Under: Cardiovascular, Clinical Trials, Drug-Device Combinations, Featured, Pharmaceuticals, Vascular, Wall Street Beat Tagged With: Abbott Laboratories, Biotronik, Boston Scientific, Elixir Medical Corporation, Reva Medical

IN CASE YOU MISSED IT

  • Abbott could pave new roads in diabetes management with dual sensor on the horizon
  • Tandem Diabetes Care pairs t:slim X2 pump with Abbott FreeStyle Libre 3 Plus in U.S.
  • Ypsomed, CamDiab to integrate Abbott dual glucose-ketone sensor into automated insulin delivery system
  • PharmaSens, SiBionics collab on all-in-one insulin patch pump
  • Beta Bionics to pair iLet automated insulin delivery system with Abbott’s dual glucose-ketone sensor

Primary Sidebar

“ddb
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in drug delivery.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

Footer

Drug Delivery Business News Logo

MassDevice Medical NETWORK

MassDevice
DeviceTalks
Medical Tubing + Extrusion
Medical Design & Outsourcing
MedTech100 Index
Drug Discovery & Development
Pharmaceutical Processing World
Medical Design Sourcing
R&D World

DRUG DELIVERY BUSINESS NEWS

Subscribe to Drug Delivery’s E-Newsletter
Advertise with us
About
Contact us
Privacy
Listen to our Weekly Podcasts

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy | RSS